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Abstract 
Recently, life-span of animals is prolonged by the progress of veterinary science, 
the improvement of feeding environment and the diffusion of vaccine. Therefore, 
various diseases such as tumors, which occur in aging animals, were increased. 
Standard treatments against tumors are surgery, radiotherapy treatment and 
chemotherapy in veterinary field same as in medical field. However, most of clinician in 
medical field and veterinary field recognize that it is impossible to treat all tumors by 
using only these three major treatments. Various therapies are studied as well as 
standard treatments in medical field. Immune therapy is the one of these new therapies. 
Immune therapy is the therapy without serious side effects and is studied and used in 
clinical field of medicine. In late years, interest for immune therapy is increased in 
veterinary field.  
Autologous Tumor Vaccines (ATVs) treatment is the one of immune therapy. In 
ATVs treatment, patients are immunized by using antigen which is extracted from own 
tumor tissue to prevent repullulation. As we can use formalin fixed tumor tissue as the 
tissue extracted antigen from, acquisition of tumor tissue is easy. In our laboratory, we 
analyzed therapy effect of ATVs treatment by using about 800 cases of spontaneity 
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tumor of canine and feline. In the study using clinical cases, I observed that minority of 
these cases did not have any effect against treatment using ATVs treatment. We 
supposed that these minority cases occurred for deficiency of amount of vaccination 
antigen and immunosuppression of animals.  
In chapter I, I found that an Hsp90-cancer antigen peptide complex was efficiently 
cross-presented by human monocyte-derived DCs and induced peptide-specific CTLs. 
Furthermore, we observed that the internalized Hsp90-peptide complex was strictly 
sorted to the Rab5+, EEA1+ static early endosome and the Hsp90-chaperoned peptide 
was processed and bound to MHC class I molecules through a endosome-recycling 
pathway. 
Hsp90 is essential for efficient cross-presentation. 
In chapter II, I found that endoplasmic reticulum (ER) disulfide oxidase ERO1-
was overexpressed in a variety of tumor types. My results suggest that overexpression 
of ERO1- -MDSCs via 
regulation of MDSC-prone cytokines and chemokines by regulating at the 
post-transcriptional level. 
From these studies, it is considered that ATVs treatment becomes more effective. 
General introduction 
Recently, life-span of animals is prolonged by the progress of veterinary science, 
the improvement of feeding environment and the diffusion of vaccine. Therefore, 
various diseases such as tumors, which occur in aging animals, were increased. 
Standard treatments against tumors are surgery, radiotherapy treatment and 
chemotherapy in veterinary field same as in medical field. However, most of clinician in 
medical field and veterinary field recognize that it is impossible to treat all tumors by 
using only these three major treatments. Various therapies such as photodynamic 
hyperthermia, hyperthermia treatment, diet therapy are studied as well as standard 
treatments in medical field. Immune therapy is the one of these new therapies. Immune 
therapy is the therapy without serious side effects and is studied and used in clinical 
field of medicine. In late years, interest for immune therapy is increased in veterinary 
field.  
Autologous Tumor Vaccines (ATVs) is the one of immune therapy. In ATVs, 
patients are immunized by using antigen which is extracted from own tumor tissue to 
prevent repullulation (Kim et al., 1998). As we can use formalin fixed tumor tissue as 
the tissue extracted antigen from, acquisition of tumor tissue is easy. In medical field, 
simpleness of acquisition affects attention as the new therapy for tumor. In our 
laboratory, we analyzed therapy effect of ATVs by using about 800 cases of spontaneity 
tumor of canine and feline. Majority of these cases were prolonged in overall survival 
and disease free survival. However, we observed that minority of these cases did not 
have any effect against treatment using ATVs. We supposed that these minority cases 
occurred for deficiency of amount of vaccination antigen and immunosuppression of 
animals. Accordingly, we hypothesize that these minority cases have good effects when 
antigenic presentation are more efficient and immunosuppression is removed. 
In this study, I performed fundamental researches to make treatment using ATVs 
into more effective treatment. I present that Hsp90 influence antigen presentation in 
chapter I, and that Endoplasmic reticulum (ER) disulfide oxidase ERO1-  influence 





Hsp90 targets a chaperoned peptide to the static early endosome for efficient 
cross-presentation by human dendritic cells. 
Abstract
The presentation of an exogenous antigen in a major histocompatibility complex 
class-I- restricted fashion to CD8+ T cells is called cross-presentation. Heat shock 
proteins (HSPs) such as Hsp70, gp96 and Hsp90 have been shown to elicit efficient 
cytotoxic T lymphocyte (CTL) responses by cross-presentation via an as yet entirely 
unknown mechanism. Hsp90 is the most abundant cytosolic HSP and is known to act as 
a molecular chaperone. We have demonstrated that a tumor antigen peptide complexed 
with Hsp90 could be cross-presented by dendritic cells (DCs) via an endosomal 
pathway in a murine system. However, it has not been determined whether human DCs 
also cross-present an Hsp90-peptide complex and induce peptide-specific CTLs. In this 
Chapter 
study, we found that an Hsp90-cancer antigen peptide complex was efficiently 
cross-presented by human monocyte-derived DCs and induced peptide-specific CTLs. 
Furthermore, we observed that the internalized Hsp90-peptide complex was strictly 
sorted to the Rab5+, EEA1+ static early endosome and the Hsp90-chaperoned peptide 
was processed and bound to MHC class I molecules through a endosome-recycling 
pathway. O
Hsp90 is essential for efficient cross-presentation.  
1. Introduction 
The generation of specific CD8+ CTLs is thought to play a key role in the control 
of virus-infected cells and tumors. However, immunization with peptides or 
recombinant proteins generally fails to elicit CTLs because an immunized antigen acts 
as an exogenous antigen. Generally, an exogenous antigen enters the MHC class II 
pathway and is presented to CD4+ T cells in the context of MHC class II molecules. 
However, professional antigen-presenting cells (APCs), particularly dendritic cells 
(DCs), can take up exogenous antigens and present them on their MHC class I 
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molecules. This process is called cross-presentation and plays an important role in the 
control of virus-infected cells and tumor growth1. There are two pathways of 
cross-presentation: cytosolic (ER-Golgi-dependent) and vacuolar (endosomal) 
pathways2, 3. One of the reasons for inefficiency of a vaccine strategy is that the vaccine 
antigen is usually administered as an exogenous antigen, and it is therefore difficult to 
introduce the vaccine antigen into the cross-presentation pathway. To overcome this 
problem, various methods have been developed to target an exogenous Ag into the 
endogenous MHC class I-restricted pathway. In our previous studies, we demonstrated 
that extracellular Hsp90-peptide complexes are efficiently cross-presented via the 
endosome-recycling pathway4. In this Hsp90-mediated cross-presentation, the 
receptor-dependent endocytosed Hsp90-peptide complex was transferred to the early 
endosome in which a cysteine protease such as cathepsin S processed the precursor 
peptide. The resulting MHC class I epitope was transferred onto recycling MHC class I 
molecules, thereby resulting in the expression of an MHC class I-epitope complex on 
the cell surface. Furthermore, we have shown that immunization with Hsp90-tumor 
antigen peptide complexes induces Ag-specific CTL responses and strong antitumor 
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immunity in vivo. However, how the Hsp90-peptide complex is sorted out after 
receptor-dependent endocytosis remains unclear. In the present work, we found that 
Hsp90 complexed with a human tumor antigen peptide derived from survivin-2B5, 6 is 
cross-presented by human monocyte-derived DCs, (Mo-DCs) resulting in the 
stimulation of peptide-specific CTLs. In addition, we found that Hsp90 targets a 
chaperoned antigen peptide into the -DCs, resulting 
in cross-presentation of the antigenic peptide through the recycling pathway.  
2. Materials and Methods
The study protocol was approved by the Clinic Institutional Ethical Review Board 
of the Medical Institute of Bioregulation, Sapporo Medical University (Sapporo, Japan). 
The patients and their families as well as healthy donors gave informed consent for the 
use of blood samples in our research. 
2.1 Patient treatment 
The patients were vaccinated with survivin-2B80-88 (1 mg) plus Montanide ISA 51 
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(1 ml) subcutaneously four times at 14-day intervals. In addition, IFN-  (3,000,000 IU) 
was administered subcutaneously twice a week close to the site of vaccination. 
Montanide ISA 51 was purchased from Seppic (Paris, France) and IFN-  was purchased 
from Dainippon-Sumitomo Pharmaceutical Co. (Osaka, Japan). Hematological 
examinations were conducted before and after each vaccination. 
2.2 Induction of human monocyte-derived immature dendritic cells.  
Autologous monocytes were purified from peripheral blood mononuclear cells 
(PBMCs) from each patient that were isolated using 
. Monocytes (1 x 104/well) in a 24-well plate were cultured in complete 
RPMI-1640 with 10% FCS and 
for 7 days. The medium with GM-CSF and IL-4 was gently replaced on day 2 and day 4. 
2.3 Peptides and proteins.  
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The following peptides were used (underlined sequences representing the precise 
MHC class I-binding epitope): survivin-2B80-88 (AYACNTSTL), survivin-2B75-93 
(GPGTVAYACNTSTLGGRGG). All peptides were purchased from SIGMA genosys 
(Ishikari, Japan). Human Hsp90 was purchased from StressGen (Ann Arbor, MI). 
Human low-density lipoprotein (LDL) was purchased from SIGMA-Aldrich (St. Louis, 
MO) and stored at 20 mg/ml in PBS at -80°C.
2.4 Antibodies.  
Confocal laser microscopy was used to detect organelles with specific antibodies: 
an anti-Rab5 pAb (MBL, Nagoya. Japan) and EEA1 (Abcam, Cambridge, MA) for 
early endosomes and anti-LAMP-1 pAb (Santa Cruz Biotechnology, Santa Cruz, CA) 
for late endosomes/lysosomes. Alexa Fluor 594 (Molecular Probes, Eugene, OR) was 
used for labeling Hsp90 and LDL.  
2.5 Generation of Hsp90-peptide complex in vitro. 
As previously described4, Hsp90 was mixed with survivin-2B75-93 
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(GPGTVAYACNTSTLGGRGG) in a 50:1 peptide to protein molar ratio in 0.7 M NaCl 
containing sodium-phosphate buffer and heated at 45°C for 30 min and then incubated 
for 30 min at room temperature.  
2.6 Establishment of survivin-2B80-88-specific CTL clone. 
We generated survivin-2B80-88-specific CTL clones from a patient with colon 
cancer (patient 1 in Table 1). PBMCs after the fourth vaccination were isolated from 
blood samples by Ficoll-Conray density gradient centrifugation. PHA blasts were 
derived from PBMCs by culturing in AIM-V medium (Invitrogen Corp., Carlsbad, CA) 
containing 10% human serum, IL-2 (100 units/mL) (Takeda Pharmaceutical Co. Osaka, 
Japan) and PHA (1 mg/mL, Wako Chemicals, Osaka, Japan) for 3 days, followed by 
washing and cultivation in the presence of IL-2 (100 units/ml) for 4 days. 
HLA-A*2402-survivin-2B80-88 peptide tetramer (MBL)-positive CTLs were sorted and 
subsequently cloned to single cells using FACSAria (Becton Dickinson, San Jose, CA). 
Survivin-2B80-88-specific CTL clones were restimulated with survivin-2B80-88
peptide-pulsed PHA blasts every 7 days in AIM-V supplemented with 50 U/ml of IL-2. 
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2.7 In vitro cross-presentation assay. 
Human Mo-DCs (1 x 105) were pulsed with Hsp90 (400 g/ml), survivin-2B75-93
(400 g/ml) alone, a complex of Hsp90 (100 g/ml or 400 g/ml) and survivin-2B75-93
(100 g/ml or 400 g/ml), a simple mixture of both or survivin-2B80-88 (400 g/ml) for 
2 h at 37°C in 100 l of Opti-MEM and then fixed for 1 min with 0.01% glutaraldehyde. 
Fixation was stopped by addition of 2 M L-lysine and the cells were washed 2 times 
with RPMI-1640 medium and cultured overnight with 1x105 survivin-2B 
peptide-specific CTL clone. Activation of CTLs was measured as IFN-  production 
using ELISA. In a dose titration assay, Mo-DCs (1 x 105) were loaded with various 
doses of survivin-2B80-88 peptide or Hsp90-precursor peptide (survivin-2B75-93) complex 
for 2 h in 100 l of Opti-MEM and fixed with 0.01% glutaraldehyde. The cells were 
washed and cultured overnight with 1 x 105 survivin-2B80-88-peptide-specific CTL clone. 
IFN-  in the culture supernatant was measured using ELISA. 
2.8 In vitro stimulation of PBMCs with Mo-DC loaded with Hsp90-precursor peptide 
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complex. 
PBMCs were isolated from eight patients suffering from various types of cancer 
who had been vaccinated with survivin-2B peptide in our clinical study7, 8. These 
s were shown to contain survivin-2B-specific CD8+ T cells. PBMCs 
were stimulated with Mo-DCs loaded with survivin-2B80-88 (400 g/ml), Hsp90 (400 
g/ml), survivin-2B75-93 (400 g/ml), and Hsp90 (100 g/ml or 400 
g/ml)-survivin-2B75-93 (100 g/ml or 400 g/ml) complex in AIM V medium (Life 
Technologies Corp, Grand Island, NY, USA) containing 10% human serum. IL-2 was 
added at a final concentration of 50 U/mL on days 2, 4, and 6. On day 7 of culture, the 
PBMCs were analyzed by tetramer staining and ELISPOT assay. 
2.9 Assessment of stimulation of antigen-specific CTLs using tetramer assay. 
FITC-labeled HLA-A*2402-human immunodeficiency virus (HIV) peptide 
(RYLRDQQLL) and PE-labeled HLA-A*2402-survivin-2B80-88 peptide tetramers were 
purchased from MBL. For flow cytometric analysis, PBMCs, which were stimulated in 
vitro as described above, were stained with HIV tetramer or survivin-2B tetramer at 
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37°C for 20 min. Then a PE-Cy5-conjugated anti-CD8 antibody (eBioscience, San 
Diego, CA) was added at 4°C for 30 min. Cells were washed twice with PBS. After 
washing, cells were fixed with 0.5% paraformaldehyde and analyzed by flowcytometry 
using FACScalibur and CellQuest software (Becton Dickinson, San Jose, CA). CD8+
living cells were gated and cells labeled with survivin-2B tetramer were referred to as 
tetramer-positive cells. The frequency of CTL precursors was calculated as the number 
of tetramer-positive cells divided by the number of CD8+ T cells.  
2.10 Assessment of stimulation of antigen-specific CTLs using ELISPOT assay. 
ELISPOT plates were coated sterilely overnight with anti-IFN-  capture antibody 
(BD Biosciences, San Jose, CA) at 4°C. The plates were then washed once and blocked 
with AIM-V medium containing 10% human serum for 2 h at room temperature. 
CD8- s (5 x 103 cell/well), which were 
stimulated in vitro as described above, were then added to each well along with 
HLA-A24-transfected T2 (T2-A24) cells (5 x 104 cells/well) that had been preincubated 
with survivin-2B80-88 (10 g/ml) or HIV with an HIV peptide as a negative control. 
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After incubation in a 5% CO2 humidified chamber at 37°C for 24 h, the wells were 
washed vigorously five times with PBS and incubated with a biotinylated anti-human 
IFN-  antibody (R&D systems, Minneapolis, MN) and horseradish 
peroxidase-conjugated avidin. Spots were visualized and analyzed using KS ELISPOT 
(Carl Zeiss, Jena, Germany). 
2.11 Immunocytological localization of Hsp90-survivin-2B75-93 peptide complex.  
Hsp90 and LDL were conjugated with Alexa Fluor 594 (Molecular Probes) 
-DCs were incubated at 37°C with 
Alexa Fluor 594 labeled-Hsp90 (20 g) complexed with survivin-2B75-93 peptide (20 
g) for 1 h. Following incubation, cells were washed twice with ice-cold PBS and fixed 
with ice-cold acetone for 1 min. Organelles were stained with an anti-Rab5 pAb and 
EEA1 mAb for early endosomes and anti-LAMP-1 pAb for late endosomes followed by 
Alexa 488-conjugated goat anti-rabbit IgG (Molecular Probes) or anti-mouse IgG 
(Molecular Probes) and then visualized with a Bio-Rad MRC1024ES confocal scanning 
laser microscope system (Bio-Rad, Richmond, CA). For evaluation of colocalization, a 
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single z-plane of one cell was evaluated. For each protein and organelle combination, a 
total of 150 cells (50 cells from three independent experiments) were analyzed.  
2.12 Inhibition studies 
Mo-DCs were pre-incubated with chloroquine (SIGMA-Aldrich) or primaquine 
(ICN Biomedicals, Irvine, CA) at 37°C for 2 h, and then loaded with survivin-2B80-88
peptide alone or Hsp90-precursosr peptide (survivin-2B75-83) complex for 2 h. The 
Mo-DCs then fixed, washed and cultured overnight with survivin-2B80-88-specific CTL 
clone. Activation of CTLs was measured as IFN-  production using ELISA. 
2.13 Statistical analysis 
All experiments were independently performed three times in triplicate. Results are 
shown as means +SEM. Comparisons between two groups were performed using 
t test, with a p value less than 0.05 considered to be statistically significant.   
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3. Results
3.1 Hsp90-survivin-2B75-93 peptide complex is cross-presented by Mo-DCs in vitro.  
We first examined whether human Hsp90 facilitated cross-presentation of the 
chaperoned precursor peptide by human Mo-DCs. Mo-DCs were pulsed with Hsp90 
alone, the survivin-2B75-93 precursor peptide alone, a simple mixture of both, a complex 
of them generated in vitro at double concentration, or survivin-2B80-88 peptide (for 
positive control) for 2 h at 37°C and then fixed, washed, and cultured with 
survivin-2B80-88-specific CTL clone. The Hsp90-survivin-2B75-93 precursor peptide 
complex elicited a significant amount of IFN-  production both at 100 g/ml and 100 
g/ml, while Hsp90 alone, survivin-2B75-93 precursor peptide alone or simple mixture of 
both did not induce IFN-  production by CTLs (Fig. 1A). Strikingly, IFN-  production 
induced by Hsp90-survivin-2B precursor peptide complex was much greater than that 
induced by survivin-2B peptide. These results indicated that cross-presentation of 
survivin-2B-derived peptide was enhanced when an exogenous precursor peptide was 
complexed to Hsp90. To confirm these observations, we compared the efficacy of CTL 
activation between survivin-2B80-88 peptide and Hsp90-survivin-2B75-93 precursor 
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peptide complex in a dose titration assay (Fig. 1B). We observed that stimulation of the 
survivin-2B80-88-specific CTL clone with Hsp90-survivin-2B75-93 precursor peptide 
complex was more effective than stimulation with survivin-2B80-88 peptide at any dose. 
3.2 Peptide-specific precursor CTLs are activated by cross-presentation of 
Hsp90-peptide complex.  
Since we demonstrated that Hsp90-survivin-2B75-93 precursor peptide complex was 
efficiently cross-presented, we next examined whether cross-presentation of 
Hsp90-peptide complex could activate and expand peptide-specific memory CD8+ T 
cells from patients who had been vaccinated with survivin-2B peptide with IFA. 
Activated and expanded survivin-2B-specific CD8+ T cells were detected by tetramer 
staining. As shown in Fig. 2, the survivin-2B75-93 precursor peptide chaperoned by 
Hsp90 was able to activate and expand survivin-2B-specific memory CD8+ T cells more 
vigorously than was the precursor peptide alone. Interestingly, peptide-specific T-cell 
frequency was higher when stimulated with Hsp90-survivin-2B75-93 precursor peptide 
complex than that with survivin-2B80-88 peptide, indicating that a long peptide 
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chaperoned by Hsp90 was efficiently cross-presented and was able to stimulate 
peptide-specific CD8+ T cells. To confirm these observations, we compared the efficacy 
of activation of survivin-2B-specific memory CD8+ T cells by stimulation with 
survivin-2B80-88,  survivin-2B75-93 precursor peptide, or Hsp90-survivin-2B75-93
precursor peptide complex in eight patients. As shown in Table 1, stimulation with 
Hsp90-survivin-2B75-93 complex could expand survivin-2B-specific memory CD8+ T 
cells from seven out of eight patients compared with stimulation with survivin-2B75-93. 
More importantly, in six out of eight patients, stimulation with Hsp90-survivin-2B75-93
complex expanded survivin-2B-specific memory CD8+ T cells more efficiently 
compared with stimulation with survivin-2B80-88.
3.3 Memory CD8+ T cells activated by cross-presentation of Hsp90-peptide complex 
become functional peptide-specific CTLs.  
To further confirm whether survivin-2B-specific CD8+ T cells activated by 
Hsp90-mediated cross-presentation were functional or not, we carried out an ELSPOT 
assay using CD8+ T cells from patient who had been vaccinated with survivin-2B 
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peptide with IFA. Figure 3 shows that stimulation of CD8+ T cells from patient with 
Hsp90-survivin-2B75-93- precursor peptide complex clearly increased 
functionally-positive survivin-2B-specific CD8+ T cells compared with stimulation with 
survivin-2B75-93 precursor peptide or survivin-2B80-88 peptide. When CD8+ T cells from 
the patient were stimulated with Hsp90 (400 g/ml)-precursor peptide (400 g/ml) 
complex, the number of IFN- -positive spots was less that of CD8+ T cells stimulated 
with Hsp90 (100 g/ml)-precursor peptide (100 g/ml) complex. These results were due 
to the formation of fused large spots that was observed when stimulated with Hsp90 
(400 g/ml)-precursor peptide (400 g/ml) complex and therefore the number of 
ELISPOT counted became smaller than that of Hsp90 (100 g/ml)-precursor peptide 
(100 g/ml) complex. These findings indicated that Hsp90-peptide complex is 
efficiently cross-presented by human Mo-DCs and is capable of stimulating 
peptide-specific CTLs.        
3.4 Immunocytological localization of Hsp90- survivin2B75-93 peptide complex.  
For further support of the above-described results, we investigated the intracellular 
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routing of Hsp90 after uptake of it in DCs, using confocal laser microscopy. Mo-DCs 
were incubated with Alexa 594-labeled Hsp90- survivin2B75-93 peptide complex for 1 hr. 
Following incubation, the cells were fixed and stained with antibodies against markers 
for organelle structures including EEA1, Rab5, and LAMP-1. Alexa 594-labeled 
Hsp90-peptide complex was detected in EEA1+, Rab5+-early endosomes but not in 
lysosomes (Fig. 4A). Quantitative analysis of the colocalization between the exogenous 
Hsp90-peptide complex and Rab5, EEA1, and LAMP1 revealed average colocalization 
incidences of 78.0%, 88.7% and 7.3%, respectively, providing further evidence that the 
exogenous Hsp90-peptide complex was delivered to the endosome-recycling pathway 
(Fig. 4B). We also examined the dynamics of Alexa 594-labeled LDL as a positive 
control protein for the dynamic early endosomal pathway (Fig. 5A and 5B). 
Alexa594-labeled soluble LDL localized to the Rab5+-early endosome as well as the 
LAMP-1+-late endosome/lysosome, but not to the EEA1+-compartment, thus indicating 
the dynamic endosomal pathway. These results indicated that the Hsp90-peptide 
complex was sorted into the static endosomal pathway, not the dynamic endosomal 
pathway, within human Mo-DCs. In contrast, the soluble LDL protein, which underwent 
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degradation, was translocated to the dynamic endosomal pathway. These results 
early endosome was required for efficient 
cross-presentation by Mo-DCs.  
3.5 Hsp90-peptide complex is cross-presented by human DCs via an 
endosome-recycling pathway. 
We then examined whether Hsp90-precursor peptide complex was cross-presented 
by human Mo-DCs via an endosomal pathway after targeting to the static early 
endosome. We used chloroquine for inhibition of endosomal acidification and 
primaquine for inhibition of the membrane recycling pathway. As shown in Fig. 6A, 
Mo-DCs that were pre-incubated with increasing concentrations of chloroquine 
completely blocked cross-presentation of Hsp90-survivin-2B75-93 precursor peptide 
complex but had no substantial effect on survivin-2B80-88 peptide presentation. These 
results indicated that cross-presentation of Hsp90-precursor peptide complex depended 
on endosomal acidification, possibly including proteolysis by endosomal proteases. 
Moreover, Mo-DC incubated with primaquine could not present the Hsp90-chaperoned 
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precursor peptide-derived survivin-2B80-88 peptide to CTL (Fig. 6B). These results 
indicated that the Hsp90-chaperoned precursor peptide or processed peptide entered 
recycling endosomes and were transferred onto recycling MHC class I molecules. 
4. Discussion 
It has been demonstrated that immunization with tumor-derived HSPs or HSPs 
complexed with an antigen peptide/protein elicits tumor- or antigen-specific CD8+ T 
cell responses1, 9. Importantly, it has been shown that Hsp70- and gp96-antigen 
complexes facilitate antigen presentation in association with MHC class I molecule10-13. 
Recently, we3, 4 14 have demonstrated that Hsp90 also acted as 
an excellent navigator for associated antigens to enter the cross-presentation pathway in 
murine system. We here showed that human Hsp90-cancer antigen peptide complex was 
efficiently cross-presented by human Mo-DCs. These results hold promise for the 
development of a safe and efficient immunomodulator for cancer immunotherapy. More 
importantly, we showed that translocation of Hsp90-Ag complex into the static early 
endosome after endocytosis was crucial for efficient cross-presentation. It has been 
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shown that the pathway for cross-presentation is comprised of two distinct intracellular 
routes, a proteasome-TAP-dependent pathway and an endosome-recycling pathway2, 3. 
Recent studies have revealed the pathway in which peptide exchange onto recycling 
MHC class I molecules occurs within early endosomal compartments15. We have shown 
that Hsp90-peptide complex-mediated4 and ORP150-peptide complex-mediated16
cross-presentation was independent of TAP and was sensitive to primaquine, indicating 
that sorting of peptides onto MHC class I occurs via an endosome-recycling pathway.  
Very recently, Lakadamyali et al.17 have shown that early endosomes are comprised of 
two distinct populations: a dynamic population that is highly mobile on microtubules 
and matures rapidly toward the late endosome and a static population that matures much 
more slowly. Cargos destined for degradation, including LDL, EGF, and influenza virus, 
are internalized and targeted to the Rab5+, EEA1--dynamic population of early 
endosomes as we have observed using LDL, thereafter trafficking to Rab7+-late 
endosmes. In contrast, the recycling ligand transferrin is delivered to Rab5+, 
EEA1+-static early endosomes, followed by translocation to Rab11+-recycling 
endosomes. Furthermore, Burgdorf et al. clearly demonstrated that a mannose receptor 
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introduced OVA specifically into an EEA-1+, Rab5+-stable early endosomal 
compartment for subsequent cross-presentation18. In contrast, pinocytosis conveyed 
OVA to lysosomes for class II presentation. Of interest, OVA endocytosed by a 
scavenger receptor did not colocalize with EEA1 but colocalized with LAMP-1 in 
lysosomes, leading to presentation in the context of MHC class II molecules. We 
showed that the human Hsp90-peptide complex is targeted into Rab5+, EEA1+-early 
endosomes after internalization by Mo-DCs, suggesting that preferential sorting to the 
 endosome is necessary for cross-presentation of Hsp90-peptide complexes. In 
contrast, soluble LDL protein was targeted to the EEA1- and LAMP-1+-dynamic early 
endosome-late endosome/lysosome pathway, leading to degradation and presentation in 
the context of MHC class II molecules. These findings suggested that Hsp90 shuttled 
the chaperoned precursor peptide into the static endosome-recycling pathway, 
preventing further degradation, followed by transfer of the peptide onto recycling MHC 
class I molecules.  Together, our findings indicate that the role of Hsp90 in 
cross-presentation is to navigate the associated antigen into static early endosomes 
within human Mo-DCs. Thus, Hsp90 appears to be a promising natural 
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immunoactivator for use of cancer vaccine development due to its excellent ability to 





 Figure Legends 
FIGURE 1. Cross-presentation of Hsp90-chaperoned peptides by human Mo-DCs. (A) 
Human monocyte-derived DCs (1x105) were pulsed with Hsp90 (400 g/ml), precursor 
peptide survivin-2B75-93 (400 g/ml) alone, a complex of Hsp90 (100 g/ml or 400 
g/ml) and survivin-2B75-93 (100 g/ml or 400 g/ml), a simple mixture of both or 
survivin-2B80-88 peptide (for positive control) for 2 h at 37°C and then fixed with 0.01% 
glutaraldehyde, washed, and cultured with survivin-2B80-88-specific CTL clone 
(1x105/well).  Activation of CTLs was measured as IFN-  production using ELISA. 
(B) Mo-DCs (1 x105) were loaded with various doses of survivin-2B80-88 peptide (6, 25, 
100, and 400 g/ml) or Hsp90-survivin-2B75-93 precursor peptide complex (6/6, 25/25, 
100/100 and 400/400 g/ml) for 2 h in 100 l of Opti-MEM and fixed with 0.01% 
glutaraldehyde. The cells were washed and cultured overnight with 1 x105
survivin-2B80-88-specific CTL clone. Activation of CTLs was measured as IFN-
production using ELISA. Data are shown as means +SEM of three independent 
experiments. *, p < 0.01. 
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FIGURE 2. Peptide-specific precursor CTLs were activated by cross-presentation of 
Hsp90-peptide complex. PBMCs were isolated from patient 1 suffering from colon 
cancer (Table 1) who has been vaccinated with survivin-2B80-88 peptide in our clinical 
study. The s were shown to contain the survivin-2B-specific CD8+ T 
cells. PBMCs were stimulated with Mo-DCs loaded with survivin-2B80-88 (400 g/ml), 
Hsp90 (400 g/ml), survivin-2B75-93 precursor peptide (400 g/ml), and Hsp90 (400 
g/ml)-survivin-2B75-93 precursor peptide (400 g/ml) complex in AIM V medium 
containing 10% human serum and IL-2 (50 U/ml) for 7 days. The stimulated PBMCs 
were stained with HIV tetramer or survivin-2B tetramer at 37°C for 20 min. Then a 
PE-Cy5-conjugated anti-CD8 antibody was added at 4°C for 30 min. Cells were washed 
twice with PBS. After washing, cells were fixed with 0.5% paraformaldehyde and 
analyzed by flowcytometry using FACScalibur and CellQuest software (Becton 
Dickinson, San Jose, California, USA). CD8+ living cells were gated, and cells labeled 
with sirvivin-2B tetramer were referred to as tetramer-positive cells. The frequency of 
CTL precursors was calculated as the number of tetramer-positive cells divided by the 
number of CD8+ cells. Data are shown as means + SEM of three independent 
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experiments. *, p < 0.01. 
FIGURE 3. Memory CD8+ T cells activated by cross-presentation of Hsp90-peptide 
complex became functional peptide-specific CTLs.  CD8-positive T cells separated 
fro s (5 x 103 cells/well) were stimulated with Mo-DCs 
loaded with survivin-2B80-88 (400 g/ml), Hsp90 (400 g/ml), precursor peptide 
survivin-2B75-93 (400 g/ml), and Hsp90 (100 g/ml or 400 g/ml)-survivin-2B75-93
(100 g/ml or 400 g/ml) complex, were added to each well along with 
HLA-A24-transfected T2 (T2-A24) cells (5 x 104 cells/well) that had been preincubated 
with survivin-2B80-88 (10 g/ml) or HIV with an HIV peptide as a negative control. 
After incubation in a 5% CO2 humidified chamber at 37 C for 24 h, the wells were 
washed vigorously five times with PBS and incubated with a biotinylated anti-human 
IFN-  antibody and horseradish peroxidase-conjugated avidin. Spots were visualized 
and analyzed using KS ELISPOT (Carl Zeiss, Jena, Germany). Data are shown as 
means + SEM of three independent experiments. *, p < 0.01. 
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FIGURE 4. Hsp90-survivn-2B75-93 precursor peptide complex localized to static 
early endosomes within human Mo-DCs. A, Human-Mo-DCs were incubated at 37°C
with Alexa 594-labeled Hsp90-survivin-2B75-93 peptide complex for 1 h and then 
washed and fixed. Organelles were stained with an anti-EEA1 mAb for early 
endosomes, anti-Rab5 pAb for early endosomes, and anti-LAMP-1 pAb for late 
endosomes/lysosomes followed by Alexa 488-conjugated goat anti-rabbit IgG or 
anti-mouse IgG and were visualized with confocal laser microscopy. Colocalization of 
the internalized Hsp90-survivin-2B75-93 peptide complex and each organelle is indicated 
by arrowheads. B, To quantify the percentage of colocalization, a single z-plane of one 
cell was evaluated. For each protein and organelle combination, a total of 150 cells (50 
cells from three independent experiments) were analyzed. Data are shown as means 
+SEM of three independent experiments. *, p < 0.01. 
Figure 5. LDL was targeted to the dynamic early endosome followed by 
translocation to the late endosome/lysosome for degradation. A, Mo-DCs were 
incubated at 37°C with Alexa 594-labeled LDL. Organelles were stained with an 
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anti-EEA1 mAb, anti-Rab5 pAb, and anti-LAMP-1 pAb, followed by Alexa 
488-conjugated goat anti-rabbit IgG or anti-mouse IgG. Colocalization of internalized 
LDL and each organelle is indicated by arrowheads. B, To quantify the percentage of 
colocalization, a single z-plane of one cell was evaluated. For each protein and 
organelle combination, a total of 150 cells (50 cells from three independent 
experiments) were analyzed. Data are shown as means +SEM of three independent 
experiments. *, p < 0.01. 
Figure 6. Hsp90-peptide complex is cross-presented via an endosome-recycling 
pathway. 
A and B, Mo-DCs were pre-incubated with chloroquine (A) or primaquine (B) at 37°C
for 2 h and then loaded with survivin-2B80-88 peptide alone or Hsp90-survivin-2B75-93
precursor peptide complex for 2 h. The Mo-DCs were then fixed, washed and cultured 
overnight with survivin-2B80-88-specific CTL clone. Activation of CTL was measured as 
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Table 1. Quantitation of survivin-2B-specific CD8 T cells by tetramer assay
in vitro stimulation (-) survivin-2B80-88 Hsp90 survivin-2B75-93 Hsp90-survivin-2B75-93
1 Colon 0.06 4.87 4.47 3.24 8.47 **
2 Colon 0.32 2.87 0.77 4.01 1.30
3 Pancreas 0.70 6.27 1.70 1.88 6.64 **
4 Pancreas *
5 Ampulla of Vater 1.27 4.60 0.97 2.24 6.50 **
6 Breast 3.59 3.78 3.00 3.06 3.82 **
7 Breast 3.98 3.91 1.94 2.28 6.19 **
8 Breast 2.76 3.92 2.91 2.08 6.07 **
*Frequency of survivin-2B-specific CD8 T cell stimulated with Hsp90-survivin-2B75-93 peptide complex was increased compared with stimulation with survivin-2B75-93 precursor peptide
** Frequency of survivn-2B-specific CD8 T cell stimulated with hsp90-survivin-2B75-93 peptide was increased compared with stimulation with both survivin-2B80-88 peptide and survivin-2B75-93 peptide.
Patient no. Tumor Survivin-2B80-88-specific CD8 T cell frequency (tetramer staining) Effect
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Cancer-associated oxidoreductase ERO1-  drives the production of 
tumor-promoting myeloid-derived suppressor cells via oxidative protein folding. 
Abstract 
Endoplasmic reticulum (ER) disulfide oxidase ERO1- plays a role in the 
formation of disulfide bonds in collaboration with PDI. The disulfide bond formation is 
required for the proper conformation and function of secreted and cell surface proteins. 
We found that ERO1-  was overexpressed in a variety of tumor types. Therefore, we 
examined the role of ERO1- in tumor growth. In BALB/c mice, knockdown of 
ERO1-  within 4T1 mouse mammary gland cancer cells (KD) caused retardation of in 
vivo tumor growth compared with tumor growth of scrambled control cells (SCR). In 
contrast, when ERO1- -overexpressed 4T1 cells (OE) were compared with mock 
control cells (mock), OE showed augmented tumor growth compared with mock. 
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However, differences of tumor growth were not observed among four groups of nude 
mice, suggesting that expression of ERO1-  diminished antitumor immunity. We 
observed dense peritumoral granulocytic infiltrates in tumors of wild-type 4T1 and SCR 
but not KD, and these cells were identified as polymorphonuclear myeloid-derived 
suppressor cells (PMN-MDSCs). In addition, production of G-CSF and CXCL1/2, 
which have intramolecular disulfide bonds, from KD was significantly decreased 
compared with that from SCR. In contrast, OE produced a larger amount of these 
molecules that did mock. These changes were regulated at the post-transcriptional level. 
These results suggest that overexpression of ERO1- in the tumor inhibits T cell 
response by recruiting PMN-MDSCs via regulation of MDSC-prone cytokines and 
chemokines. 
1. Introduction 
The tumor microenvironment has been shown to be an immunosuppressive 
microenvironment. Myeloid-derived suppressor cells (MDSCs) are a major component 
of the immune-suppressive network in cancer and many other pathological conditions. 
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Experimental models using mice have shown that MDSCs can facilitate tumor 
progression by promoting the suppression of antitumor immunity1-4, promoting 
inflammation4, 5, stimulating angiogenesis6, and enhancing tumor cell migration and 
metastasis7. Clinical studies have further demonstrated that the presence of MDSCs 
correlates with adverse outcomes and shorter survival in various types of cancer, 
including breast cancer8. MDSCs are a heterogeneous group of myeloid cells 
characterized by potent immunosuppressive activity. In mice, they are characterized as 
CD11b+ Gr-1+ cells. In recent years, two major groups of cells that comprise MDSCs 
have been identified: cells with morphology and phenotype (CD11b+ Ly6Clow Ly6G+) 
typical of polymorphonuclear-PMN-MDSCs and cells with morphology and phenotype 
(CD11b+ Ly6Chigh Ly6G-) typical of monocytes-Mo-MDSCs. Mo-MDSCs consist of 
immature myeloid cells with the ability to differentiate to macrophages and DCs. 
PMN-MDSCs are the largest population of MDSCs in tumor-bearing mice, representing 
>75% of all MDSCs. They suppress antigen-specific T cell response, primarily via 
release of ROS. PMN-MDSCs have also been found in cancer patients. Thus, 
PMN-MDSCs play a pivotal role in tumor progression. However, the underlying 
Chapter II 
mechanism by which PMN-MDSCs proliferate and infiltrate into tumor sites has been 
unclear. G-CSF is a cytokine with potent neutrophil proliferation activity. G-CSF is 
produced by macrophages, fibroblasts and endothelial cells. Recently, it has been shown 
that tumor cells are a source of G-CSF9-12 and that production of G-CSF by tumors is 
responsible for the recruitment of immunosuppressive PMN-MDSCs, which promote 
tumor growth via inhibition of antitumor immune responses13, 14. A vital role of 
tumor-derived G-CSF in tumor bearing mice was demonstrated by Waight et al.13  In 
addition, depletion of G-CSF resulted in reduced tumor growth in a murine mammary 
gland cancer 4T1 model. 4T1 cells were previously shown to express a G-CSF 
transcript. Thus, G-CSF is a candidate molecular target of cancer treatment.  
ERO1-  is an ER-resident oxidase. ERO1-  and PDI play a central role in 
disulfide bond formation of secreted and cell surface molecules15-18. Disulfide bond 
formation, i.e., oxidative protein folding, is the most common post-translational 
modification and is required for proper conformation and function of these molecules. 
Thus, these secreted and cell surface molecules need to be regulated by not only the 
gene expression level but also proper post-transcriptional modification. We have 
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recently demonstrated that various types of tumor cells expressed high levels of 
ERO1-  and that ERO1-  is a poor prognostic marker for breast cancer19. Here we 
demonstrate that ERO1-  plays a pivotal role in PMN-MDSCS induction via 
upregulation of G-CSF production from cancer cells in collaboration with PDI. 
2. Materials and methods 
2.1 Cells  
The murine breast cancer cell line 4T1 and human breast cancer lines MCF7, 
BT-474, UACC-893, SK-BR-3, MDA-MB-157, MDA-MB-231, MDA-MB-468 were 
purchased from ATCC (Manassas, VA, USA). 4T1, BT-474 and MDA-MB-157 cells 
were cultured in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA), MCF7, 
MDA-MB-231 and MDA-MB-468 cells were cultured in Dulbecco s modified Eagle s 
medium (Sigma-Aldrich), UACC-893 cells were cultured in Leibovitz's L-15 (Life 
Technologies, Carlsbad, CA, USA) and SK-BR-3 cells were 
media (Life Technologies) supplemented with 10% FCS at 37  in 5% CO2. Short 
hairpin RNA for murine ERO1-  (TR502816) was purchased from OriGene (Rockville, 
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MD, USA) and transfected to 4T1 cells using Lipofectamine RNAiMAX (Life 
Technologies). Cells were stably propagated under puromycin selection (6 µg/ml). The 
murine ERO1-  gene fragment was isolated from pCMV6-Entry Vector/mERO1-
(OriGene) digested with BamH1 and Xho I, and then inserted into an appropriate site of 
the expression vector pcDNA6/myc-HisA (Invitrogen, Carlsbad, CA, USA). The 
resulting pcDNA6/mERO1-  or an empty vector as a control was transfected into 4T1 
cells using Lipofectamine 2000 (Life Technologies). Cells were stably propagated under 
blasticidin (5 g/ml, Life Technologies) selection.  
2.2 In vivo study 
Female BALB/c and BALB/c nu/nu mice, 4 weeks old, were obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA) and used at 5 weeks of age. Mice were 
maintained in a specific pathogen-free mouse facility at Sapporo Medical University 
(Sapporo, Japan) according to institutional guidelines for animal use and care. For 
tumor formation studies, mice were injected with 3×104 4T1 cells, ERO1- - 
overexpressed cells (OE) or ERO1-  (KD) into the right 4th mammary 
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glands. Tumor growth was measured 2-3 times/week in two dimensions, and tumor 
volume was calculated using the formula 3.14 x (width2 x length)/6. Tumor length and 
width were measured with a caliper.  
2.3 Treatments 
Mice were challenged with 3×104 4T1 SCR cells. For the depletion of CD4+ and/or 
CD8+ T cells, mice were injected intraperitoneally with a CD4-specific antibody and/or 
CD8-specific antibody at 200 g/mouse on day 3 before and day 1 after tumor 
challenge. For depletion of Ly6G+ PMN-MDSCs, mice were injected intraperitoneally 
with Ly6G-specific antibody clone 1A8 (Bio X Cell, West Lebanon, NH, USA) or Rat 
IgG (Sigma-Aldrich) at 100 g/mouse every 2 days from day 15 after the tumor 
challenge.  
2.4 Quantitative reverse transcription-PCR (qPCR) analysis and real-time PCR 
Total RNA was isolated from cultured cells and normal breast tissues using Isogen 
reagent (Nippon Gene, Tokyo, Japan) and RNeasy Mini kits (QIAGEN, Valencia, CA) 
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total RNA by reverse transcription using Superscript III and oligo (dT) primer (Life 
Technologies
performed in 20 µl of PCR mixture containing 1 µl of cDNA mixture, 0.1 µl of Taq 
DNA polymerase (QIAGEN) and 6 pmol of primers. Real time-relative quantitative 
polymerase chain reaction (qPCR) was performed with a QuantiTect SYBR Green PCR 
Kit (QIAGEN) to determine the expression levels of cxcl1, cxcl2, g-csf and -actin. 
Expression values for each sample were -actin, and fold levels of the 
indicated genes represent the mean (±SEM) of replicate reactions. Primer sequences 
were as follows: -actin (actb), QuantiTect Mm Actb 1 SG Primer Assay; cxcl1, 
QuantiTect Mm_Cxcl1_1_SG Primer Assay; cxcl2, QuantiTect Mm_Cxcl2_1_SG; g-csf 
(Csf3), QuantiTect Mm_Csf3_1_SG (QIAGEN). PCR cycles were performed on the 
StepOne Real-Time PCR System (Life Technologies) with the following cycle 
conditions: 10 min at 95°C, 45 cycles of 15 s at 95°C and 1 min at 60°C, followed by 
melting curve analysis. The delta-delta Ct method was used for data analysis.  
Real time-relative polymerase chain reaction (real-time PCR) was performed to 
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determine the expression levels of ERO1-  and -actin. Expression values for each 
sample wer -actin, and fold levels of the indicated genes represent the 
mean (±SEM) of replicate reactions. Primer sequences were as follows: -actin (ACTB), 
Hs0160665_g1; ERO1-  (ERO1L), Hs00205880_m1 (Life Technologies). PCR cycles 
were performed on the StepOne Real-Time PCR System (Life Technologies) with the 
following cycle conditions: 2 min at 50 °C, 10 min at 95°C, 40 cycles of 15 s at 95°C 
and 1 min at 60°C. The delta-delta Ct method was used for data analysis. 
2.5 Western blot analysis.  
Cultured cells were washed in ice-cold PBS, lysed by incubation on ice in a lysis 
buff -HCl [pH 7.5 ], 
and cleared by centrifugation at 21880g for 30 min at 4°C. For blockade of free thiols, 
cells were pretreated for 5 min with 10 mM methyl methanethiosulfonate (Pierce, 
Rockford, IL, USA) in PBS. Post-nuclear supernatants were divided and heated for 5 
min at 95°C in a non-reducing or reducing SDS sample buffer, resolved by SDS-PAGE, 
and electrophoretically transferred to PVDF membranes (Immobilon-P; Millipore, 
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Billerica, MA, USA). The membranes were incubated with blocking buffer (5% non-fat 
dried milk in PBS) for 30 min at room temperature and then incubated overnight with 
anti-ERO1- aipei, Taiwan), anti-PDI polyclonal antibody (Enzo Life 
Sciences, Farmingdale, NY, USA), anti-mG-CSF (R&D Systems, Minneapolis, MN, 
USA), or mouse anti- -actin mAb AC-15 (Sigma-Aldrich, St. Louis, MO, USA). After 
washing three times with wash buffer (0.1% Tween-20 in TBS), the membranes were 
reacted with peroxidase-labeled goat anti-rabbit IgG antibody, peroxidase-labeled goat 
anti-mouse IgG antibody or peroxidase-labeled rabbit anti-goat antibody (KPL, 
Gaithersburg, MD, USA) for 3 h. Finally, the signal was visualized using an ECL 
detection system (Amersham Life Science, Arlington Heights, IL, USA) or 
IMMOBILON detection system (Millipore Corporation, Billerica, Massachusetts, USA) 
according to the manufacturers s.  
2.6 Analyses of leukocytic infiltrates in the tumor and flow cytometry 
Mice were injected with 1×105 4T1 cells, ERO1- -overexpressed cells or ERO1-
knockdown cells into the right 4th mammary glands. Tumor tissues, peripheral blood, 
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spleen and bone marrow were collected on day 14 after the tumor challenge. For 
analyses of leukocytic infiltrates in the tumor tissue, tumors were mechanically 
dissociated on a wire mesh by crushing with scissors and digested for 2 to 3 h at 37 °C 
in RPMI medium supplemented with 5% fetal bovine serum and Liberase (Roche, 
Tokyo, Japan) (1 mg/ml).  Then leukocytes were collected by density-gradient 
centrifugation with lympholyte-M. Peripheral blood, spleen cells and bone marrow were 
hemolyzed by a hemolytic agent. The cells were filtered through 70 µm nylon strainers 
(BD Biosciences, Bedford, MA) and counted the cell number. They were then stained 
with specific markers, and analyzed by flow cytometry. All preparations were 
pre-incubated with anti-CD16/32 mAb (BD Biosciences, San Diego, CA) to block Fc 
receptor binding, followed by incubation with a directly conjugated primary antibody. 
Labeled cells were analyzed by a FACSCalibur flow cytometer (BD, San Jose, CA) and
FlowJo (Tree Star Inc., Oregon, USA). Antibodies reactive against the following cell 
surface markers were used (including appropriate isotype controls): PE-labeled CD11b, 
PerCP/Cy5.5-labeled Ly6G and APC-labeled Ly6C (BioLegend, San Diego, CA) and 
PerCP/Cy5.5-labeled Gr-1 (eBioscience, San Diego, CA). 
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2.7 Immunohistochemistry 
Tissue was fixed in neutral 10% buffered formaldehyde, embedded in paraffin, and 
cut into 5- -thick slices for ERO1- ing. Reactivity of the anti-ERO1-
monoclonal antibody was determined by perinuclear staining within tumor cells, 
indicating endoplasmic reticulum localization. Tissues were frozen with OCT 
compound (Leica Biosystems, Nussloch, Germany) and cut into 7-µm-thick slices for 
CD11b and Gr-1 staining. Antibodies reactive against CD11b and Gr-1 were purchased 
from BioLegend and eBioscience, respectively. Secondary antibodies were purchased 
from DAKO Japan (Tokyo, Japan). Tissue sections were developed using a 
diaminobenzidine. Images were quantified by counting the number of positively stained 
cells in five randomly selected fields at × 200 magnification. 
2.8 Enzyme-linked immunosorbent assay (ELISA). 
4T1 cells were plated at 1 × 105 -well plates for 24 h or 48 h. All 
samples were stored at -80°C until assayed. Supernatants were diluted and mouse 
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CXCL-1 (GRO/KC) (IBL, Gunma, Japan), mouse CXCL-2 (MIP- ) and mouse 
G-CSF (R&D Systems, Minneapolis, MN, USA) levels were measured using a 
sandwich ELISA kit. Absorbance was determined at 450 nm. 
2.9 Statistical analysis 
S -test was used for analysis of two unpaired samples. Statistical 
differences in results of the study with depletion of CD4+ and/or CD8 T+ cells were 
analyzed by Dunnett s test. Differences in the results of the study with depletion of 
Ly6G+ PMN-MDSCs were assessed by the Mann-Whitney test. Overall survival rates 
were calculated by the Kaplan Meier method, and differences in survival curves were 
assessed by the log rank test. All analyses were carried out with STATMATE version 
3.19 (ATMS Co., Ltd., Tokyo, Japan). A P-value of less than 0.05 was regarded as 
statistically significant. All statistical tests were two-sided. 
3. Results 
3.1 Expression of ERO1- in breast cancer cell lines and breast cancer tissues. 
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We have shown that ERO1-  expression was augmented in human breast cancer 
cell lines and breast cancer tissues19. Here we showed the expression of ERO1-  on 
breast cancer cell lines was upregulated regardless of the histological type compared 
with the expression in normal breast tissues at the mRNA level (Fig. 1A). 
Immunohistochemical staining also showed that ERO1-  was preferentially expressed 
within tumor cells but not normal breast tissue (Fig. 1B, 1C). Our previous study 
demonstrated that none of the normal breast tissues (71 cases) were positive for 
ERO1-  staining19.We have observed that ERO1-  showed a patchy staining pattern 
within cancer nests. As it has been demonstrated that ERO1-  is induced under the 
condition of hypoxia, we assumed that cancer cells residing within hypoxic areas show 
augmented expression of ERO1- . Thus, heterogeneity of ERO1-  expression seems to 
be attributed to the oxygen and blood supply. 
3.2 Knockdown of ERO1-
antitumor T-cell-mediated immunity. 
To examine the role of ERO1-  in tumor growth, we generated ERO1-
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knockdown cells (KD) using shRNA against ERO1-  (Fig. 2A). KD cells did not show 
differences in a proliferation assay compared with wild-type 4T1 (WT) cells and 
scrambled shRNA-transfected (SCR) cells (Supplemental Fig. 1). When BALB/c nu/nu 
mice were challenged with SCR cells and KD cells, we observed that these two cell 
lines grew aggressively at similar growth speeds (Fig. 2B). In contrast, knockdown of 
ERO1-  caused retardation of tumor growth compared with WT cells in BALB/c mice 
(Fig. 2C). Knockdown of ERO1-  also had a survival benefit compared with SCR cells 
(Fig. 2D). These results suggested that ERO1-  (+) WT or SCR tumor cells inhibited 
antitumor immunity. In other words, depletion of ERO1-  within tumor cells might 
restore antitumor immunity. To clarify this, we performed a T-cell depletion assay in 
vivo. When CD4+ and/or CD8+ T cells were depleted during tumor growth assay using 
KD cells, these cells showed tumor growth similar to that of SCR cells, indicating that 
both CD4+ and CD8+ T cells were responsible for the immunogenicity of KD tumor 
cells (Fig. 3A). Moreover, since some of the mice challenged with KD cells rejected the 
tumors, we rechallenged these mice with 4T1 WT cells. All of the mice rechallenged 
with 4T1 tumor cells rejected tumor cells (Fig. 3B), indicating that KD tumor cells 
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acted as immunogenic tumor cells due to ERO1-  knockdown. Based on these results, 
both CD4+ and CD8+ T-cell-mediated antitumor immunity against 4T1 tumor was 
dampened by the expression of ERO1-  within 4T1 tumor cells.  
3.3 Enhanced expression of ERO1-  promotes the tumor growth in vivo via suppression 
of antitumor immunity. 
To further confirm the effect of ERO1-  on tumor growth and antitumor immunity, 
we generated an ERO1- -overexpressed 4T1 cell line (OE) by introducing murine 
cDNA of ERO1-  (Fig. 4A). When 4T1 cells transfected with a control vector (mock) 
and OE cells were inoculated to nude mice, there was no difference in tumor growth 
rates (Fig. 4B), but, when they were inoculated to BALB/c WT mice, OE tumors grew 
more aggressively than did mock cell tumors (Fig. 4C, 4D). These results again 
suggested that expression of ERO1-  suppressed antitumor immunity against the 4T1 
tumor. 
3.4 PMN-MDSCs accumulate in the spleen, bone marrow, peripheral blood, and tumor 
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of ERO1-  (+) 4T1 tumor-bearing mice. 
Histopathological findings revealed that ERO1-  (+) SCR 4T1 tumor tissues had a 
large amount of granulocyte infiltrates in the peritumor site as well as within the tumor 
mass (Fig. 5A). In clear contrast, KD tumors showed less granulocyte infiltrates (Fig. 
5B). We compared peritumoral and intratumoral infiltrating cells in SCR and KD 
tumors by immunohistochemical analysis using CD11b mAb and Gr-1 mAb. Although 
we observed that the major component was CD11b+ Gr-1+ MDSCs both in ERO1- (+) 
SCR tumors and KD tumors, total numbers of both CD11b+ cells and Gr-1+ cells were 
increased in SCR tumors (Fig. 5C, 5E, 5G) compared with those in KD tumors (Fig. 5D, 
5F, 5H). Furthermore, we investigated the population of these infiltrates using a flow 
cytometer. Interestingly, Ly6G+ polymorphonuclear MDSCs (PMN-MDSCs) were 
predominantly observed in the spleen (40.9% vs 17.2%), bone marrow (67.0% vs 
57.7%), peripheral blood (57.6% vs 23.7%), and tumor (45.2% vs 27.9%) in SCR 
tumor-bearing mice compared with those in KD tumor-bearing mice (Fig.6A, 6B, 6C, 
6D and supplemental Table 1A). In contrast, when we compared mice bearing mock 
tumors and OE tumors, we observed that PMN-MDSC infiltration was higher in OE 
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tumor-bearing mice than that in mock-bearing mice in the spleen (31.0% vs 18.1%), 
bone marrow (61.6% vs 60.4%), peripheral blood (50.3% vs 22.3%), and tumor (49.5% 
vs 37.6%) (Fig. 7A, 7B, 7C, 7D and supplemental Table 1B). These results suggested 
that the expression of ERO1-  within the tumor resulted in accumulation of 
PMN-MDSC throughout the body including the spleen, bone marrow, peripheral blood 
as well as the tumor, leading to the suppression of antitumor T-cell-mediated immunity 
by PMN-MDSCs. 
3.5 Depletion of Ly6G+ PMN-MDSCs renders tumor cells immunogenic. 
To determine whether Ly6G+ MDSCs were the main immunosuppressor cells in 
the 4T1 tumor system, we depleted Ly6G+ cells during the tumor growth assay using 
anti Ly6G mAb (1A8). Although depletion of Ly6G+ cells seemed incomplete, about 
50% of Ly6G+ cells remained in the peripheral blood (supplemental Fig.2), apparently, 
depletion of Ly6G+ cells retarded SCR tumor growth compared with the growth of 
isotype-matched control IgG-treated tumors, and SCR tumor growth was almost the 
same as tumor growth in mice challenged with KD cells (Fig. 8). These results indicated 
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that (tumor-associated) Ly6G+ PMN-MDSCs were the main immunosupressor cells for 
ERO1-  (+) 4T1 tumor cells.  
3.6 Tumor ERO1-  plays a crucial role in the induction and recruitment of 
PMN-MDSCs. 
We examined the mechanism of induction of tumor-associated PMN-MDSCs. 
Since it was demonstrated that G-CSF and GM-CSF induce proliferation of 
PMN-MDSCs1, 13, 14, we measured the production G-CSF and GM-CSF from 4T1 tumor 
cells using ELISA. We found that ERO1 (+) SCR cells produced a large amount of 
G-CSF compared with the amount produced by the KD cells (Fig. 9A). In addition, 
albeit to the lesser extent, production of GM-CSF from SCR cells was shown to be 
greater than that from KD cells (supplemental Fig. 3A). Whereas G-CSF amplifies 
PMN-MDSCs in the spleen, bone marrow and peripheral blood, PMN-MDSCS 
recruitment from the circulation to tumor stroma is thought to occur mainly via 
interaction between the chemokines CXCL1 and CXCL220, 21 and their receptor CXCR2 
expressed on PMN-MDSCs20. Therefore, we compared the concentrations of CXCL1 
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and CXCL2 in the culture supernatant of each cell line. SCR cells produced a larger 
amount of CXCL1 and CXCL2 for PMN-MDSCS recruitment than did KD cells (Fig. 
9B, 9C). In contrast, when we compared mock cells and OE cells, OE cells showed 
greater production of G-CSF, CXCL1, and CXCL2 than did mock (Fig. 9D, 9E, 9F). As 
expectedly, PMN-MDSCs in the spleen, bone marrow and peripheral blood expressed 
CXCR2 (supplemental Fig. 3B). These results suggested that tumor-derived G-CSF 
induced proliferation of PMN-MDSCs followed by recruitment to the tumor sites by 
augmented production of CXCL1 and CXCL2, resulting in the inhibition of antitumor 
T-cell-mediated immune response.  
3.6 Tumor ERO1-  facilitates the production of G-CSF and CXCL1 and 2 via oxidative 
folding at the post-transcriptional level.  
We investigated the role of ERO1-  in the augmented production of G-CSF, 
CXCL1, and CXCL2. To determine whether the gene expression level was affected by 
ERO1- , we compared the g-csf mRNA expression levels by real-time RT-PCR. The 
mRNA expression levels were not different in mock cells and OE cells, indicating that 
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the expression of ERO1-  did not influence the g-csf gene expression level (Fig. 10A). 
In addition, we observed that the gene expression levels of cxcl1 and cxcl2 were not 
altered (Fig. 10A). Next, we compared the protein levels using Western blot analysis. 
Since ERO1-  is known to act as an oxidoreductase, we further investigated the redox 
states of G-CSF in mock cells and OE cells by Western blot analysis under a 
non-reducing condition using MMTS. We found that the total amount of G-CSF protein 
in OE cells was larger than that in mock cells under a reducing condition (Fig. 10B). 
Moreover, we found that ratio of the oxidized form (mature form) to the reduced form 
(immature form) of G-CSF in OE cells was much higher than that in mock cells under a 
non-reducing condition (Fig. 10B). It has been shown that G-CSF has two 
intramolecular disulfide bonds22 and that the disulfide bond formation is required for 
G-CSF to exert its biological activity. Taking this into account, these results indicated 
that tumor ERO1-  plays a pivotal role in the generation of disulfide bonds within 
G-CSF at the post-transcriptional level but not at the gene expression level. Thus, tumor 
ERO1-  plays a crucial role in the proper folding of G-CSF, leading to the augmented 
production of G-CSF. To further confirm our observations, we compared the gene 
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expression levels of g-csf, cxcx1, and cxcl2 in SCR and KD cells. As expected, we did 
not observe any differences in mRNA levels of these genes between the two cell lines 
(Fig. 10C). In addition, we compared the redox states of G-CSF in SCR and KD cells. 
We found that the total amount of G-CSF protein in KD cells was much less than that in 
SCR cells under a reducing condition (Fig. 10D). Furthermore, both the reduced form 
and oxidized form of ERO1-  were clearly decreased in KD cells compared with those 
in SCR cells under a non-reducing condition . We speculated that the decrease in the 
total amount of G-CSF protein in KD tumor cells was due to degradation through 
ER-associated degradation because the immature reduced form of protein is destined to 
proteasomal degradation. This will be examined in the future. We concluded that 
tumor-associated ERO1-  facilitated the oxidative folding of factors including G-CSF, 
CXCL1m and CXCL2 for the induction and recruitment of PMN-MDSCs, resulting in 
the inhibition of antitumor T-cell response. 
4. Discussion 
Oxidative protein folding characterized by intramolecular disulfide bond formation 
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is the most common post-transcriptional modification18. A proper disulfide 
configuration provides the structural foundation for more nuanced intramolecular 
folding events that define protein activity23. Most of the proteins that are secreted or 
expressed on the cell surface have intramolecular disulfide bonds. Thus, oxidative 
protein folding is critical for normal cell function and homeostasis. Among the 
oxidoreductases expressed in the ER, ERO1-  is central to oxidative protein folding, but 
its expression varies in a tissue-specific manner19. Moreover, it has been shown that 
ERO1-  is upregulated under a hypoxic condition24, 25, which is frequently observed in 
a cancer microenvironment. Furthermore, we previously showed that ERO1-  is 
overexpressed in various types of cancer cells line and cancer tissues19. Since cancer 
cells may take advantage of factors that are induced within hypoxic environments or at 
different stages of carcinogenesis, these finding led us to hypothesize that 
overexpression of ERO1-  might be functionally important for tumor cells, promoting 
further exploration of the role that ERO1-  might play in cancer progression. In this 
study, we found that suppression of ERO1-  protein resulted in a dramatic reduction of 
tumor growth using a mouse mammary gland cancer 4T1 model. Since the expression 
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of ERO1-  did not seem to play a major role in tumor cell growth in vitro or in vivo
tumor growth using nude mice, massive infiltration of PMN-MDSCs was considered to 
contribute to tumor growth in BALB/c mice. In fact, an in vivo depletion assay using 
anti-Ly6G, anti-CD4 or anti-CD8 mAbs and a tumor rechallenge assay clearly showed 
that PMN-MDSCs inhibited anti-tumor T-cell responses. Since ERO1-  is a sulfhydryl 
oxidase26, it is unlikely that ERO1-  would directly induce proliferation of 
PMN-MDSCs. Therefore, we measured levels of cytokines and chemokines responsible 
for the induction or recruitment of PMN-MDSCs in the culture supernatant. 4T1 tumor 
cells secreted a large amount of G-CSF. In contrast, ERO1-  knockdown cells showed 
decreased secretion of G-CSF, CXCL-1, and CXCL-2. Based on these results, we 
hypothesized that ERO1-  is involved in the proper oxidative protein folding of G-CSF 
before it is secreted and that the loss of ERO1-  leads to functionally inactive G-CSF 
(reduced form) as shown by Western blotting under a non-reducing condition (Fig. 10D). 
To further confirm that what we observed is a post-transcriptional event, we conducted 
real-time RT-PCR on SCR cells and KD cells. We did not observe any differences in 
mRNA levels of these genes between the two cell lines, suggesting that ERO1-  acted 
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at the post-translational level. Since ERO1- -expressing 4T1 cells may affect the 
function of MDSCs through the production of some cytokines, this possibility should be 
investigated in the near future. 
ERO1-  was previously reported by our group to be overexpressed in breast cancer 
tissues and to be useful as a poor prognostic marker19. Many tumors, including breast 
cancer, have the capacity to promote immune tolerance and escape host immune 
surveillance2. Tumors utilize numerous pathways to inhibit immune responses, 
including the elaboration of immune inhibitory cytokines such as IL-10 and TGF- , as 
well as inducing host cells to release immune inhibitors. In addition to these 
mechanisms, immune suppression through MDSCs has a crucial role in promoting 
tumor progression1.  
In this study using a mouse mammary gland carcinoma 4T1 model, we showed 
that ERO1-  contributes to suppression of anti-tumor immunity through upregulation of 
G-CSF and CXCL1/2 via facilitation of oxidative protein folding. We did not determine 
whether ERO1-  is solely responsible for the proper oxidative folding of these 
molecules or whether it cooperates with protein disulfide isomerase (PDI) while these 
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molecules are folding in the ER and Golgi. These questions need to be clarified. While 
further research is still needed to understand the role of ERO1- in vivo, the results 







 Figure legends 
Figure 1. 
Expression of ERO1-
with that in normal breast tissue.  (A) Human ERO1-
cell lines (Luminal type: MCF7, BT-474, UACC-893; HER2 type: SK-BR-3; Triple 
negative breast cancer: MDA-MB-157, MDA-MB-231, MDA-MB-468) and normal 
breast tissue determined by real-time PCR. Data represent means ±SEM. * P<0.05, 
-test. Data are representative of three independent experiments. (B) 
Normal breast tissue and (C) breast cancer tissue were stained for ERO1-
inset:× 200). Representative micrographs were shown.  
Figure 2. 
 Knockdown of ERO1- s. 
(A) Western blot analysis of 4T1 (WT) cells, scrambled shRNA-transfected (SCR) and 
ERO1-  rates of SCR and KD cells were 
compared using BALB/c nu/nu mice (five mice/group). Data represent means ±SEM. 
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(C) Tumor growth rates of SCR and KD cells were compared using BALB/c mice 
(eleven mice/group). Data represent means ±SEM. (D) Overall survival rates of SCR 
and KD cells were analyzed using BALB/c mice (twelve mice/group, scarified when 
tumor volume was over 800 mm3). Data represent means ±SEM. * p < 0.01, unpaired 
-test. The experiment was repeated three times with essentially the same 
results. 
Figure 3. Expression of ERO1-  the tumor suppressed both CD4- and 
CD8-dependent cellular immunity.  
(A) Mice were challenged with 3 × 104 4T1 SCR cells (five mice) or KD cells (twenty 
mice) into the left 4th mammary glands. For the depletion of CD4 and/or CD8 T cells, 
mice were divided into four groups (five mice/group) injected intraperitoneally with a 
rat IgG as a control, a CD4-specific antibody and/or CD8-specific antibody at 200 
mouse on day 3 before and day 1 after tumor challenge. Data represent means ±SEM. 
# p s test. (B) Mice that ERO1- -challenged 
with 3 × 104 4T1 cells into the left 4th mammary glands (five mice). As a control, 
Chapter II 
BALB/c mice cells were challenged with 3 x 104 4T1 cells into the left 4th mammary 
glands (five mice). Tumor length and width were measured with a caliper. Data 
represent means ±SEM. p < 0.001, Mann-Whitney  test. The experiment was repeated 
three times with essentially the same results. 
Figure 4. 
Enhanced expression of ERO1- within 4T1 cells suppressed cellular immunity against 
4T1 cells. (A) Western blot analysis of mock cells and ERO1- -overexpressed (OE) 
cells. (B) Tumor growth rates of mock and OE cells were compared using BALB/c 
nu/nu mice (five mice/group). Data represent means ±SEM. (C) Tumor growth rates of 
mock and OE cells were compared using BALB/c mice (eight mice/group). Data 
represent means ±SEM. (D) Overall survival rates of mock and OE cells were analyzed 
using BALB/c mice (thirteen mice/group, scarified when tumor volume was over 800 
mm3). * p -test. The experiment was repeated three times 
with essentially the same results. 
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Figure 5. 
Expression of ERO1-  significantly promoted peritumoral and intratumoral infiltration 
of CD11b+ and Gr-1+ granulocytic cells. The amount of peritumoral infiltration of 
inflammatory cells in SCR (A) was larger than that in KD (B) (x 40, inset: x 100). 
Immunohistochemical staining for CD11b (C, D) and Gr-1 (E, F) in SCR (C, E) and KD 
(D, F) tumor tissues (x 40, inset: x 100). (G) CD11b+ cells in peritumoral and 
intratumoral sites were counted in five fields at x 200 magnification. Data represent 
means ±SEM. (H) Gr-1+ cells in peritumoral and intratumoral sites were counted in five 
fields x 200 magnification. Data represent means ±SEM. * p < 0.001, Mann-Whitney 
test. Data are representative of three independent experiments. 
Figure 6. 
 Knockdown of ERO1- -MDSCs in the 
body and peritumoral infiltration of PMN-MDSCs. (A) Splenocytes, (B) bone marrow, 
(C) peripheral blood leukocytes and (D) tumor-infiltrating leukocytes that expressed 
CD11b were divided into CD11b+ Ly6Ghi and Ly6Cint cells by flowcytometric analysis. 
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3 × 104 events in splenocytes, bone marrow and peripheral blood leukocytes were
analyzed, and 2.5 × 104 events in tumor-infiltrating leukocytes were analyzed. Data are 
representative of three independent experiments. 
Figure 7. 
Enhanced expression of ERO1- amount of 
PMN-MDSCs in the body and peritumoral infiltration of PMN-MDSCs. (A) 
Splenocytes, (B) bone marrow, (C) peripheral blood leukocytes and (D) 
tumor-infiltraing leukocytes that expressed CD11b were classified into CD11b+ Ly6Ghi
and Ly6Cint cells by flowcytometric analysis. 2.5 × 104 events in splenocytes, bone 
marrow, peripheral blood leukocytes and tumor-infiltrating leukocytes were analyzed. 
Data are representative of three independent experiments. 
Figure 8. 
Expression of ERO1-  the 
number of PMN-MDSCs in the body. Tumor growth rates of three groups were 
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compared using BALB/c mice (five mice/group). Mice were injected intraperitoneally 
with an Ly6G- ouse every 2 days from day 15 
EM. * p < 0.001, 
Mann-Whitney test. The experiment was repeated three times with essentially the same 
results. 
Figure 9. 
 Expression of ERO1-  the tumor was involved in the production of G-CSF, 
CXCL1 and CXCL2. (A) Concentration of G-CSF in the 48-h culture supernatant from 
SCR or KD cells was measured using ELISA. (B) Concentrations of CXCL1 in the 24-h 
culture supernatant from SCR or KD cells was measured using ELISA. (C) 
Concentrations of CXCL2 in the 48-h culture supernatant from SCR or KD cells was 
measured using ELISA. (D) Concentration of G-CSF in the 48-h culture supernatant 
from mock or OE cells was measured using ELISA. (E) Concentrations of CXCL1 in 
the 24-h culture supernatant from mock or OE cells was measured using ELISA. (F) 
Concentrations of CXCL2 in the 48-h culture supernatant from mock or OE cells was 
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measured using ELISA. Data represent means ±SEM. * p 
t-test. Data are representative of three independent experiments. 
Figure 10. 
Expression of ERO1-  the tumor facilitated the production of CXCL1, CXCL2 
and G-CSF via oxidative folding. (A) Cxcl1, cxcl2 and g-csf mRNA levels in mock and 
OE cells determined by qPCR analysis. Data represent means ±SEM. (B) Redox status 
of G-CSF in mock and OE cells was examined by Western blotting under reducing (R) 
or non-reducing (NR) conditions. Reduced form (R) or oxidized form (O) of G-CSF is 
indicated. (C) Cxcl1, cxcl2 and g-csf mRNA levels in SCR and KD cells determined by 
qPCR analysis. Data represent means ±SEM. (D) Redox status of G-CSF in mock and 
OE cells was examined by Western blotting under reducing (R) or non-reducing (NR) 
conditions. Reduced form (R) or oxidized form (O) of G-CSF is indicated. Data are 
representative of three independent experiments. 
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Supplemental materials and methods 
In vitro tumor growth 
5 × 104 SCR and KD cells were seeded at 5 x104 per well in a 10 cm dish. After 24, 
48 and 72 h, cells were counted by using a Countess Automated Cell Counter (Life 
Technology, Carlsbad, CA, USA). 
Flow cytometry 
Peripheral blood, spleen cells and bone marrow were collected from BALB/c mice 
bearing SCR cells on day 28 after tumor challenge. Labeled 4T1 cells, peripheral blood, 
spleen cells and bone marrow were analyzed by a FACSCalibur flow cytometer (BD) 
and FlowJo (Tree Star Inc.). Antibodies reactive against the following cell surface 
markers were used (including appropriate isotype controls): PE-labeled CD11b 
(BioLegend), PerCP/Cy5.5-labeled Gr-1 (eBioscience) and APC-labeled CXCR2 (R&D 
Systems) . 
Enzyme-linked immunosorbent assay (ELISA). 
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4T1 cells were plated at 1 × 105 -well plates for 24 h. All samples 
were ouse GM-CSF (R&D Systems, Minneapolis, MN, 
USA) levels were measured using a sandwich ELISA kit. Absorbance was determined at 
450 nm. 
Statistical analysis 
-test was used for analysis of two unpaired samples. All analyses were 
carried out with STATMATE version 3.19 (ATMS Co., Ltd., Tokyo, Japan). A p-value 
of less than 0.05 was regarded as statistically significant. All statistical tests were 
two-sided. 
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Supplemental figure 1. Expression of ERO1-  within the tumor did not influence 
tumor growth in vitro. 
SCR and KD cells were seeded at 5 × 104 per well in a 10 cm dish. After 24, 48 
and 72 h, cells were counted by using a Countess Automated Cell Counter (Life 
Technology, Carlsbad, CA, USA). Data are representative of three independent 
experiments. 
There were no differences of in vitro tumor growth of SCR cells and KD cells on days 
1-3. 
Supplemental figure 2. Effect of depletion of Ly6G+ cells in peripheral blood 
leukocytes.
Peripheral blood leukocytes were collected from mice injected with the Ly6G 
antibody or rat IgG at 100 mg/mouse every 2 days from day 15 after the tumor 
challenge. They were divided into CD11b+ Ly6Ghi and Ly6Cint cells. The percentage of 
CD11b+ Ly6Ghi in mice injected with the Ly6G antibody were lower (52.3%) than that 
in mice injected with rat IgG (70.8%). Data are representative of three independent 
Chapter II 
experiments. 
Supplemental figure 3. Tumor ERO1- -CSF.
4T1 cells of SCR or KD were plated at 1 × 105 -well plates for 24 h. 
-CSF (R&D Systems, 
Minneapolis, MN, USA) levels were measured using a sandwich ELISA kit. 
Absorbance was determined at 450 nm. Data are representative of three independent 
experiments. 
The production of GM-CSF from SCR cells was shown to be greater than that from KD 
cells. * p < -test. 
Supplemental figure 4. CD11b+ and Gr-1hi cells (PMN-MDSC) expressed CXCR2 
on the cell surface.
Peripheral blood, spleen cells and bone marrow were collected from BALB/c mice 
bearing SCR cells on day 28 after tumor challenge. Flow cytometric analysis of CXCR2 
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expression on these cells (solid line). These cells incubated with APC-labeled isotype 
control served as background controls (dashed line). Data are representative of three 
independent experiments. 
Supplemental Table. 1 Expression of ERO1-  within the tumor affected the 
number of PMN-MDSCs in mice bearing the tumor.
(A) The number of PMN-MDSCs in bone marrow, spleen, peripheral blood 
leukocytes and tumor-infiltrating leukocytes in SCR group was higher than that in KD 
group. (B) The total numbers of PMN-MDSCs in bone marrow, spleen, peripheral blood 
leukocytes and tumor-infiltrating leukocytes in OE group were higher than that in mock 
group. Cells were analyzed in three independent studies. Data represent mean ± SEM. * 
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bone marrow 19896.5±464.8 17242.5±108.4*
peripheral blood leukocytes 17529.6±143.0 7324.6±552.3**





bone marrow 15279.6±260.4 15826.6±303.1**
peripheral blood leukocytes 5673.6±214.4 12125.4±721.1**




The complex of peptide and Hsp90 can induce the larger amount of 
peptide-specific CD8 T cells than only peptide and only Hsp90 via promoting cross 
presentation.  
The expression of ERO1-  in the tumor tissues inhibited immune response 
against tumors via stimulating the proliferation and recruitment of PMN-MDSCs.  
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